Ekin Kırcalı

Dr. Ekin Kırcalı

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Balkan Medical Journal
Verified
Journal Article
Open access
EKEkin Kırcalı
Ekin Kırcalı
GSGuldane Cengiz Seval
Guldane Cengiz Seval
CÖCemaleddin Öztürk
Cemaleddin Öztürk
HYHülya Yılmaz
Hülya Yılmaz
DKDerya Koyun
Derya Koyun
MYMeltem Kurt Yüksel
Meltem Kurt Yüksel
Eltrombopag has an off-label indication for haematopoietic cell transplantation in patients experiencing delayed thrombocyte recovery and/or thrombocytopaenia. To present our centre’s experience of using this agent not only for post- haematopoietic cell transplantation thrombocytopaenia but also for poor graft functioning in the post-haematopoietic cell transplantation setting. Retrospective cross-sectional study. Thirty-nine patients who had persistent cytopaenia following haematopoietic cell transplantation and treated with eltrombopag at our centre between October 2011 and December 2021 were retrospectively identified. During this period, 9 (23.1%) and 30 (76.9%) patients who underwent allogeneic transplantations, respectively, received eltrombopag. The female-to-male ratio was 12:27, and the median transplant age was 49 (18-70) years. Eight (20.5%) patients had isolated thrombocytopaenia, 19 (49.4%) had bi-lineage cytopaenia and 12 (30.1%) had pancytopaenia. Patients received a median of 50 mg/day (25-150 mg/day) of eltrombopagfor a median duration of 82 (24-386) days. Nine (23.1%) patients had autologous haematopoietic cell transplantation, and 30 (76.9%) had allogeneic haematopoietic cell transplantation (14 unrelated, 9 sibling and 7 haploidentical). The median donor age was 32 (20-67) years. The median follow-up was 16.4 (1.8-84.3) months. The median pre-treatment platelet count was 11x109/l (1-23), which increased to 41x109/l (6-150). The median platelet count increment was 29.5x109/l (p = 0.001). The pre-treatment median neutrophil count was 1.19x109/l (0.39-5.1), which increased to 2.35 x109/l (0.1-5.33) (p = 0.05), and the pre-treatment median haemoglobin was 8.3 (6.2-14) g/dl, which increased to 10 (6.2-14) g/dl (p = 0.001) with eltrombopag. No eltrombopag-related hepatotoxicity occurred; however, 1 (2.6%) patient failed to continue treatment because of two consecutive episodes of deep venous thrombosis. Six (15.4%) patients were unresponsive to eltrombopag and dependent on blood product transfusions. After a median time of 82 days, 61.5% of the patients discontinued eltrombopag successfully. The results confirmed that eltrombopag could provide a rapid, sustained response in patients with poor graft functioning after haematopoietic cell transplantation. This finding is essential given the high rate of non-relapse mortality caused by poor graft functioning after haematopoietic cell transplantation.

3 November 2026 in Upsala Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
ECEsra Cengiz
Esra Cengiz
EKEkin Kırcalı
Ekin Kırcalı
RARifat Furkan Aydın
Rifat Furkan Aydın
MÇMurat Çınarsoy
Murat Çınarsoy
Background: Daratumumab, an immunoglobulin G kappa (IgG-κ) monoclonal antibody, can co-migrate with endogenous M-protein on serum immunofixation (IF), producing IgG-κ bands that may be misinterpreted as residual disease. We therefore evaluated treatment responses and the prognostic impact of daratumumab-associated IgG-κ IF positivity on progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Methods: We retrospectively analyzed 108 patients with MM treated with daratumumab-containing regimens at any line of therapy between January 2014 and January 2024. Serum IF IgG-κ positivity was assessed both at the first response assessment and during continued treatment. Treatment responses were classified according to the International Myeloma Working Group (IMWG) criteria, and PFS and OS were analyzed using the Kaplan–Meier method, the log-rank test, and multivariable Cox proportional hazards regression. Results: IgG-κ IF positivity was detected in 85 patients (78.7%) at first response, and the overall response rate to daratumumab was 64.8%. Patients positive at first response had longer PFS (14.0 vs. 7.0 months; P = 0.048) and higher very good partial response/complete response rates (65.9% vs. 43.5%; P = 0.058). In non–IgG-κ myeloma, treatment-emergent positivity was associated with a markedly higher deep-response rate (88.5% vs. 44.2%; P < 0.001) and a reduced risk of progression (hazard ratio 0.17; 95% confidence interval 0.03–0.74; P = 0.018). On multivariable analysis, older age independently predicted mortality, whereas persistent IF positivity did not worsen survival. Conclusions: IgG-κ IF positivity during daratumumab therapy should not be interpreted as residual disease in isolation; a substantial proportion likely reflects therapeutic antibody interference. Recognizing this interference is important to avoid overestimating residual disease and misclassifying treatment response, and confirmatory assays should be used where available.

1 December 2023 in LLM Dergi
Verified
Journal Article
Closed access
EKEkin Kırcalı
Ekin Kırcalı
STSelami Koçak Toprak
Selami Koçak Toprak
PTPervin Topçuoğlu
Pervin Topçuoğlu

7 February 2025 in Intercontinental Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
EKEkin Kırcalı
Ekin Kırcalı
ZÇZeynep Kendi Çelebi
Zeynep Kendi Çelebi
ŞEŞiyar Erdoğmuş
Şiyar Erdoğmuş
KKKenan Keven
Kenan Keven
NDNeval Duman
Neval Duman
Aims: This study aims to evaluate changes in systolic pulmonary artery pressure (sPAP) in end-stage renal disease (ESRD) patients before and after kidney transplantation, as well as the prevalence and impact of pulmonary hypertension (pHT) on post-transplant outcomes. Methods: A total of 87 ESRD patients undergoing kidney transplantation at the Nephrology Department of Ankara University Faculty of Medicine were prospectively followed. Demographic data, pretransplant, and posttransplant (3rd and 12th months) serum tests, as well as echocardiographic measurements, were analyzed. Patients with pHT due to non-renal causes were excluded. Mean systolic pulmonary artery pressure was measured echocardiographically and a level of above 30 mmHg was accepted as pHT. Statistical analyses were performed using SPSS, with a p-value <0.05 considered statistically significant. Results: Among the 87 patients, 40 (45.9%) were male and 47 (54.1%) were female, with a mean age of 42.6±11.7 years. The mean pretransplant sPAP was 36.6±7.97 mmHg, which decreased significantly to 31.7±5.5 mmHg at 3 months and 30.1±6.2 mmHg at 12 months post-transplant (p<0.05). Pretransplant pHT was present in 72.4% of patients, which reduced to 36.7% at 3 months and 22.9% at 12 months post-transplant. Preoperative triglyceride and parathormone levels were significantly correlated with sPAP (p<0.05), while patients with pretransplant sPAP ?40 mmHg had a higher incidence of early graft dysfunction (p<0.05). Conclusion: Pulmonary hypertension is prevalent in patients with ESRD but significantly decreases after kidney transplantation. Patients with preoperative sPAP ?40 mmHg are at higher risk for early graft dysfunction, highlighting the importance of screening for pHT in transplant candidates. Addressing pHT in ESRD patients may improve post-transplant outcomes, reduce morbidity, and enhance overall patient management.

17 December 2021 in Journal of Ankara University Faculty of Medicine
Verified
Journal Article
Closed access
GSGuldane Cengiz Seval
Guldane Cengiz Seval
EKEkin Kırcalı
Ekin Kırcalı
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
MYMeltem Kurt Yüksel
Meltem Kurt Yüksel
PTPervin Topçuoğlu
Pervin Topçuoğlu
STSelami Koçak Toprak
Selami Koçak Toprak

3 December 2024 in LLM Dergi
Verified
Journal Article
Closed access
EKEkin Kırcalı
Ekin Kırcalı
SUSelin Merih Urlu
Selin Merih Urlu
UŞUğur Şahi̇n
Uğur Şahi̇n
ÖAÖnder Arslan
Önder Arslan